Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220045 | 1.00 | HPGD (0.50) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL222625 | 1.00 | HPGD (0.50) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL12272010 | 1.00 | HPGD (0.50) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL223042 | 1.00 | HPGD (0.50) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL221146 | 1.00 | HPGD (0.50) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL12186260 | 1.00 | HPGD (0.50) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2477630 | 0.96 | HPGD (0.52) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2477634 | 0.96 | HPGD (0.52) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL22720299 | 0.91 | HRH3 (0.47) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2475421 | 0.91 | HPGD (0.52) | HPGDMAPTHRH3EPHX1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533995-B2 | Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof | SANOFI (FR) | 2017-01-03 | — | — | US | disclosed |
| US-9533995-B2 | Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof | SANOFI (FR) | 2017-01-03 | — | — | US | disclosed |
| EP-2569294-B1 | SUBSTITUTED N-HETEROARYL BIPYRROLIDINE CARBOXAMIDES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-03-11 | — | — | EP | disclosed |
| EP-2569294-B1 | SUBSTITUTED N-HETEROARYL BIPYRROLIDINE CARBOXAMIDES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-03-11 | — | — | EP | disclosed |
| US-20140315923-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-10-23 | — | — | US | disclosed |
| US-20140315923-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-10-23 | — | — | US | disclosed |
| US-8859588-B2 | Substituted N-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof | SANOFI (FR) | 2014-10-14 | — | — | US | disclosed |
| US-8859588-B2 | Substituted N-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof | SANOFI (FR) | 2014-10-14 | — | — | US | disclosed |
| US-8859588-B2 | Substituted N-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof | SANOFI (FR) | 2014-10-14 | — | — | US | disclosed |
| US-8796278-B2 | Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof | SANOFI (FR) | 2014-08-05 | — | — | US | disclosed |
| US-20100173949-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| US-20100173949-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| US-20100173949-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| US-20100173908-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| WO-2010065803-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONES USED AS H3 MODULATORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | WO | disclosed |
| WO-2009052068-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052068-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052065-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052062-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052065-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173949-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | HPGD 1406/4885MEN1 3865/4885ALDH1A1 911/4885 |
| US-20140315923-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | CHRM2, NR3C2, NPSR1 | HPGD 438/4885MEN1 2415/4885ALDH1A1 646/4885 |
| US-20100173908-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | HRH3, HRH4, UTS2R | HPGD 1099/4885MEN1 4133/4885ALDH1A1 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.